Hepatology

HEPATOLOGY DIGEST: Right, so through these integrative efforts we might be able to control the progression of liver cancer, right?

Hepatology Digest: Thank you both. It was a pleasure and I hope to see you next year.

Hepatology Digest: The last thing I would like to ask you about is sorafenib .

Hepatology Digest: how do you think the clinical practice of proteinase inhibitors ? Will the side effects affect its clinical use?

Hepatology Digest: The liver is known as an immunologically privileged organ in solid organ transplants.

Hepatology Digest: From your experience, RFA is an efficient treatment for HCC. What are the indications and contraindications for RFA?

Hepatology Digest: The reason I ask is that there is a bit of a mixed message here. Red wine is promoted as a good anti-oxidant for example.

Hepatology Digest: Professor Jia, do you know of any similar compounds that are being researched in China?

Hepatology Digest: It seems that most people today don't recommend switching at this point and it is more of an add-on strategy.

Hepatology Digest: The two approved DAA drugs, telaprevir and boceprevir, were thought of the first generation protease inhibitors.

Hepatology Digest: For the treatment of chronic hepatitis B patients with cirrhosis what are the issues required for special intervention?

Hepatology Digest : Could you tell us your opinion on the current state of affairs in the diagnosis of this pathology?

Hepatology Digest: Amniotic fluid is said to contain a wide variety of useful cells. Could you comment about obtaining cells in this manner?

Hepatology Digest: In the rest of the world, could you give us an update on how the hepatitis B vaccine is being applied?

Hepatology Digest: When intra-uterine transmission happens, the vaccination and hepatitis B immunoglobulin might not be functional.

Hepatology Digest: At present, interventional therapy is still the more effective treatment strategy for unresectable HCC patients.

Department of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore.

Hepatology Digest: What are the differences between antiviral treatment in pre-transplant and post-transplant in HBV patients?

Hepatology Digest : Could you provide us an outline on the latest advancements on improving the management of this pathology?

Hepatology Digest: What advances in pharmacological treatment can halt progression to decompensated cirrhosis or reverse cirrhosis?

Hepatology Digest: There is now no effective treatment for Wilson's disease related liver cirrhosis besides liver transplantation.

Hepatology Digest: You mentioned one of the hot topics is the direct antivirals.

Hepatology Digest: Individualized treatment is important for chronic hepatitis C using current available direct acting antivirals (DAA).

Hepatology Digest: Can pre-transplantation antiviral treatment improve the post-transplantation survival rate?

Dept of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore.

Hepatology Digest: Following up on that: you mentioned that in 2008 the pathogenesis of non-alcoholic steatohepatitis is not necessary know.

Hepatology Digest : This year you conducted a prospective population-based surveillance to estimate newly diagnosed CLD incidence.

Hepatology Digest: Do you think HCC is a major indication for living donor transplantation? Why or why not?

Hepatology Digest: What would be your experience and approach Professor Xie?

Hepatology Digest: In the guideline, non-invasive markers may be used to measure liver disease.

Hepatology Digest: What are the potential mechanisms of HBsAg seroconversion?

Hepatology Digest: You should probably define moderate at this point. What is moderate?

Division of Hepatology, California Pacific Medical Center and ResearchInstitute, San Francisco, CA, United States.

Hepatology Digest: At present, several clinical studies of direct acting antivirals (DAA) combinations are ongoing.

HEPATOLOGY DIGEST: How do you think about the current and emerging therapies on hepatocellular cancer?

Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.

Hepatology Digest: Both host and viral factors are involved in chronic HCV infection, and escape from innate and adaptive immune responses.

The findings appear in the April issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD).

Hepatology Digest: There's a slight difference at the end of treatment numbers I believe, right?

Hepatology Digest: You mentioned that there distinct differences of CD8 T cells in HCV patients . Can you please elaborate on this?

Hepatology Digest: According to EASL 2009 guideline, HBV infection cannot be completely eradicated, due to the persistence of cccDNA.

Hepatology Digest: Studies have shown that excess expression_r_r_r_r of HBsAg and HBeAg contributed to the immune tolerance for HBV.

Hepatology Digest: Having just mentioned living donor transplantation, it seems there is a downward trend for living donor transplantation.

Hepatology Digest: How do you anticipate the timeline for it moving on to the next phase?

Hepatology Digest: Statins that lower blood cholesterol concentration can reduce the risk of heart attacks.

Hepatology Digest: Should both lactulose and rifaximin be combined for the primary prevention of HE?

Hepatology Digest: You have obviously proven a connection between suppressed immunity and alcohol, but do you know why?

Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association.

Hepatology Digest: The combination of peginterferon alpha-2a and ribavirin has a good therapeutic effect for the relapse of hepatitis C.

Hepatology Digest: You had mentioned some other ethnicities; do have information how China or the Asian population fits into that?

We have recently published a paper in Hepatology that suggests the more sick your adipose tissue is the more insulin resistant.

Hepatology Digest: Are there any specific therapeutic avenues targeting this?

Hepatology Digest: Are the effects of alcohol on the immune system a transient effect or does it have any permanent qualities to it?

Hepatology Digest: When you add those extra drugs on top of the regimen does it affect compliance?

Hepatology Digest: A number of endogenous anti- and pro-fibrogenic factors are involved in liver fibrogenesis.

Hepatology Digest: The combination of peginterferon alpha 2a and ribavirin has a good effect for the relapse of hepatitis C.

Hepatology Digest: What is the possible impact of molecular biology research on the treatment of liver fibrosis and cirrhosis?

Hepatology Digest: Liver biopsy is the gold standard for diagnosis of liver cirrhosis.

Hepatology Digest: Can you give us a brief introduction on how hepatocytes play their role in controlling systemic innate immunity?

Hepatology Digest: You mentioned side-effects, so the natural next question is: how do you balance the side effects versus the benefit?

Hepatology Digest: Induction of tolerance in B cells is also important for long-term survival of organ allografts.

Hepatology Digest: Could you please talk a little bit about the role of gene therapy in HBV?

Hepatology Digest : When we compare to other types of tumors, what are the prospects for HCC in targeted therapy?

Hepatology Digest: In your world view, what do you see as the optimal outcome for what you are doing?

Mayo Clinic's Division of Gastroenterology and Hepatology has been ranked #1 in the U. S.

HEPATOLOGY DIGEST: How about the current situation in China at the moment Professor Wei?

Hepatology Digest: And what about among different races: is there any difference in your outcomes?

Hepatology Digest: So even if the mother takes the drugs, the baby is safe?

Hepatology Digest: Non-invasive tests have been suggested in EASL 2009 guidelines for hepatitis B.

Hepatology Digest: Perhaps you should clarify for us, what is the definition of a GAVI country?

Hepatology Digest: You highlighted in your talk diabetes is a liver disease, why so?

Hepatology Digest: How about any new advances in the treatment for PBC?

International Hepatology: It is interesting you mention bariatric surgery in addition to being looked at as treatment with diabetes.

Hepatology Digest: Would you please give us some advice on how to treat patients with Cholestatic liver disease?

Hepatology Digest: It is the combination of interferon and ribavirin that will continue to play an important role.

Hepatology Digest: Are there any new drugs for HE being developed in the pipeline for the future?

Hepatology Digest: What's your view on the future of vitamin D in the treatment of patients with liver fibrosis?

Hepatology Digest: Although NAFLD is becoming more and more prevalent, it has generally been viewed as a kind of "harmless" disease.

Hepatology Digest: Organ shortage is a world problem. Can you talk about how to use methods of marginal donors to solve this problem?

Hepatology Digest: Professor Xie, do you encounter metabolic syndrome in hepatitis C patients frequently?

Hepatology Digest: Will you please give us your general over-view of the current progress in the treatment of alcoholic hepatitis?

International Hepatology: How many anti-fibrotic drugs are used in clinical practice and what is the safety and effectiveness of them?

I'm Paul Martin, Professor of Medicine, Chief of Hepatology at the University of Miami in Florida.

Hepatology Digest: You mentioned that they can induce HBeAg seroconversion, and we know that this is not a solid endpoint.

Hepatology Digest: Also in your session, there was discussion about bariatric surgery after transplant. What is your opinion about that?

Hepatology Digest: What is your opinion of non-invasive diagnosis of cirrhosis? Do you think non-invasive will instead of invasive?

Hepatology Digest: Regarding cadaveric donors, have you seen a change in the trend in availability from that source?

Hepatology Digest: What is your opinion of the role of serum antibodies in the diagnosis of autoimmune related cirrhosis?

Hepatology Digest: There is obviously a lot of talk about sorafenib at this year's meeting.

Hepatology Digest: Do you feel that it is the silibinin that reduced the viral load?

Hepatology Digest: Is it the case that there hasn't been any resistance to tenofovir?

Hepatology Digest: Would you like to comment on sequential therapy and combination therapy in the treatment of HBV drug resistance?

Group of Fatty Liver and Alcoholic Liver Disease, Branch Association of Hepatology, Chinese Medical Association.

Hepatology Digest: There are certainly various types of stem cells we can use and is there a particular preference you have and why?

Hepatology Digest: What is your opinion of transient elastography in the diagnosis of cirrhosis?

Hepatology Digest: What about in China and the use of erythropoietin?

Hepatology Digest: Is it easier to induce immunosuppression withdrawal in children or adults and why is that?

Hepatology Digest: Some patients can not achieve SVR when treated with PEG IFN for 48 weeks.

Hepatology Digest: Do you think that with more and more clinical trials regarding sorafenib, do you think it will update the guidelines?

Hepatology Digest: NAFLD is affecting more and more children both in China and America.

Hepatology Digest: Do you have any specific thoughts for Asians having to do with NAFLD?

Summary of the fifth shanghai international conference of gastroenterology and hepatology

European Society of Paediatric Gastroenterology, Hepatology and Nutrition

Evidence-based medicine and its possible influence on the therapeutics of hepatology

North American Society of Pediatric Gastroenterology, Hepatology and Nutrition

British Society of Pediatric Gastroenterology, hepatology and Nutrition

Brief introduction of the 38th congress of European Society of Pediatric Gastroenterology, Hepatology and Nutrition

Molecular Biology and Gene Therapy in Gastroenterology and Hepatology

Chinese Journal of Gastroenterology and Hepatology

Journal of Gastroenterology and Hepatology

An analysis of the impact factors of hepatology journals in SCI

Egyptian Society of Hepatology Congress

Chinese Journal of Clinical Hepatology